Advertisement

Topics

FDA approves Duzallo for treatment of hyperuricemia in patients with uncontrolled gout

07:21 EDT 21 Aug 2017 | Healio

The FDA has approved Ironwood Pharmaceuticals’ Duzallo, a combination pill of lesinurad and allopurinol, for the treatment of hyperuricemia in patients with uncontrolled gout, according to a company press release.“The approval of Duzallo provides a new fixed-dose and dual-mechanism treatment option to help patients with uncontrolled gout achieve target serum uric acid levels. This represents an important and needed new option in the treatment of hyperuricemia,” Michael A. Becker, MD, from the University of Chicago, and colleagues wrote. “Gout is a serious and potentially progressive and debilitating inflammatory disease.”

Original Article: FDA approves Duzallo for treatment of hyperuricemia in patients with uncontrolled gout

NEXT ARTICLE

More From BioPortfolio on "FDA approves Duzallo for treatment of hyperuricemia in patients with uncontrolled gout"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Gout
According to the National Arthritis Data Workgroup, an estimated 6 million people in the United States report having experienced gout at some point in their lives. In fact, gout is the most common form of inflammatory arthritis in men over the age of 40....

Rheumatology
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...